Nuvig Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $161.0Mattributed |
|---|---|
| Latest round | series-b, $161.0M, 2024-12-01attributed |
| Founded | unknown |
| Headquarters | Menlo Park CA |
| Industry | biotech|immunology|autoimmune |
| Stage | series-b+ |
| Website | nuvig.com |
Nuvig Therapeutics is a Menlo Park clinical-stage biotech developing engineered Fc fragments that mimic sialylated IgG to treat autoimmune disease. It targets CIDP patients dependent on costly IVIG infusions. Lead drug NVG-2089 binds type-II Fc receptors to match IVIG effects at far lower doses; now in Phase 2.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-12-01 | series-b | $161.0M | undisclosed |
Detected tech stack
Nginx
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $161.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $161.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | nuvig.com, read 2026-05-07 |
| Description | self-reported | nuvig.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.